跳转至内容
Merck
CN

535140

Millipore

Protease Inhibitor Cocktail III

Animal-Free, liquid, for the inhibition of aspartic, cysteine, serine proteases and aminopeptidases

别名:

Animal free Protease inhibitor

登录查看公司和协议定价

关于此项目

UNSPSC代码:
12352200
NACRES:
NA.54
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

蛋白酶抑制剂混合物套装III,无动物源性成分, Protease Inhibitor Cocktail Set III, Animal-Free, is a cocktail of six protease inhibitors with broad specificity for the inhibition of aspartic, cysteine & serine proteases & aminopeptidases.

表单

liquid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
avoid repeated freeze/thaw cycles

溶解性

water: soluble

运输

wet ice

储存温度

−20°C

一般描述

六种蛋白酶抑制剂的混合物,对天冬氨酸、半胱氨酸和丝氨酸蛋白酶以及氨基肽酶具有广泛的特异性。建议将该混合物用于哺乳动物细胞和组织提取物。每个小瓶含有100 mM AEBSF、HCl(目录号101500)、80 µM抑肽酶(目录号616371)、5 mM苯丁抑制素(目录号200484)、1.5 mM E-64(目录号324890)、2 mM亮抑蛋白酶肽(目录号108975)和1 mM胃蛋白酶抑制剂A(目录号516482)。以1 ml瓶或一组5 x 1 ml形式提供。

生化/生理作用

主要靶标
天冬氨酸、半胱氨酸和丝氨酸蛋白酶以及氨肽酶
产物不与ATP竞争。
可逆:否
细胞可渗透性:否

外形

溶于1 ml DMSO。

制备说明

初次融化后,等分并冷冻(-20°C)。

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

毒性:刺激性(B)

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Skin Irrit. 2

储存分类代码

10 - Combustible liquids

WGK

WGK 2

闪点(°F)

188.6 °F

闪点(°C)

87 °C


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Danielle T Phillippi et al.
Particle and fibre toxicology, 19(1), 10-10 (2022-02-10)
The gut microbiota plays a vital role in host homeostasis and is associated with inflammation and cardiovascular disease (CVD) risk. Exposure to particulate matter (PM) is a known mediator of inflammation and CVD and is reported to promote dysbiosis and
Li-Ping Gao et al.
ACS chemical neuroscience, 11(5), 814-829 (2020-02-13)
Mitophagy is an important process for removing damaged mitochondria in cells, the dysfunction of which has been directly linked to an increasing number of neurodegenerative disorders. However, the details of mitophagy in prion diseases still need to be deeply explored.
Ching-Hsin Huang et al.
Advanced therapeutics, 3(6) (2021-03-02)
Mono- or dual-checkpoint inhibitors for immunotherapy have changed the paradigm of cancer care; however, only a minority of patients responds to such treatment. Combining small molecule immuno-stimulators can improve treatment efficacy, but they are restricted by poor pharmacokinetics. In this
Kijun Kim et al.
STAR protocols, 3(1), 101042-101042 (2022-01-18)
We describe a protocol to conduct a high-throughput in vitro processing assay, using 1,881 human primary microRNAs (pri-miRNAs) and recombinant Microprocessor complex, followed by deep sequencing library generation. This comprehensive approach allows the mapping of cleavage sites and the measurement
Eunju Shin et al.
Biochemical and biophysical research communications, 528(1), 46-53 (2020-05-28)
GATA1 is a master transcription factor of megakaryopoiesis and erythropoiesis, and loss-of-function mutation can induce accumulation of megakaryocyte-erythroid progenitors (MEPs) in mice and humans. Accordingly, the murine MEP cell line (termed G1ME2 cells) encoding doxycycline (dox)-inducible anti-Gata1 shRNA on Hprt

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持